• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

    2/15/23 8:00:00 AM ET
    $AGRX
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AGRX alert in real time by email

    Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team

    GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

    Appointment of Ernie De Paloantonio to Chief Financial Officer Further Strengthens CPSI's Leadership Team

    Ernie brings over 30 years of financial and business experience in the pharmaceutical industry including both private and public commercial and manufacturing companies. Most recently, he was Chief Financial Officer of Journey Medical Corporation, a commercial stage dermatology company. Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.

    As CFO, Ernie will have responsibility for both finance and information technology.

    "I am pleased to be able to work with Ernie again as we look to grow this promising specialty development and manufacturing business. Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions. He will play an instrumental role working closely with myself, members of the leadership team, and our investors on our long-term growth strategy and its execution," said Mark Sirgo, CEO of CPSI, in making the announcement.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug and consumer product delivery technologies. With a track record spanning nearly 30 years, the company offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by B-FLEXION and Webster Equity Partners. Prior to the CPSI transaction with Webster Equity Partners in October 2022, Gurnet Point Capital, an affiliate of B-Flexion, led the original investment in Corium Pharma Solutions through a take-private transaction in October 2018.

    About Gurnet Point Capital & B-FLEXION

    Gurnet Point Capital, an affiliate of B-FLEXION, is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    B-FLEXION is a private, entrepreneurial investment firm, partnering with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society. The company oversees growth-oriented operating businesses and asset managers, always with an 'active owner' philosophy. B-FLEXION invests across a wide range of industries, including healthcare. Gurnet Point Capital, an affiliate of B-FLEXION, leads B-FLEXION's de-risked life sciences investment strategy.

    https://www.bflexion.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    Contact

    Gartman PR

    (202) 413-4226

    Cision View original content:https://www.prnewswire.com/news-releases/corium-pharma-solutions-names-ernie-de-paolantonio-as-chief-financial-officer-301746886.html

    SOURCE Corium Pharma Solutions Inc.

    Get the next $AGRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AGRX
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    5/1/2025$161.00Buy → Neutral
    Redburn Atlantic
    Procter & Gamble Company
    $PG
    4/25/2025$177.00Sector Perform → Outperform
    RBC Capital Mkts
    Procter & Gamble Company
    $PG
    11/25/2024$160.00 → $209.00Neutral → Buy
    DA Davidson
    Procter & Gamble Company
    $PG
    10/10/2024$159.00Neutral
    DA Davidson
    Procter & Gamble Company
    $PG
    9/30/2024$163.00Overweight → Equal Weight
    Barclays
    Procter & Gamble Company
    $PG
    9/24/2024$174.00Neutral
    Piper Sandler
    Procter & Gamble Company
    $PG
    8/29/2024$190.00Hold → Buy
    DZ Bank
    Procter & Gamble Company
    $PG
    7/24/2024$182.00 → $175.00Buy → Hold
    Jefferies
    More analyst ratings

    $AGRX
    $PG
    Leadership Updates

    Live Leadership Updates

    See more
    • IFF Appoints Virginia "Gina" Drosos to Board of Directors

      IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served

      6/9/25 5:46:00 PM ET
      $IFF
      $PG
      $SIG
      Major Chemicals
      Industrials
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G Appoints Craig Arnold to Board of Directors

      The Procter & Gamble Company (NYSE:PG) today announced the appointment of Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, to its Board of Directors, effective June 9, 2025. Mr. Arnold brings significant experience as a successful chief executive of a global enterprise serving businesses and customers in more than 175 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609584955/en/P&G Appoints Craig Arnold to Board of Directors With a distinguished career at Eaton, a global leader in power infrastructure and technology, Arnold led the company through transformative changes from 2016 to Ma

      6/9/25 4:15:00 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Tide Teams Up with Marvel Studios to Highlight Stain Stories and Host Exclusive, First-Ever "Collateral Stains Screening" Experience for Marvel Studios' Captain America: Brave New World

      Tide Launches Most Powerful Clean and Best Stain Removal POD – in any Universe: Ultra Oxi Boost Power PODS Throughout the Marvel Cinematic Universe (MCU), collateral stains are a way of life. And, in the highly anticipated Marvel Studios' "Captain America: Brave New World," in theaters February 14, everyday people in the MCU sometimes have to face clouds of dirt, spilled coffee and guacamole stains that occur by virtue of being courtside to action-packed superhero moments. That's why Tide®, America's #1 trusted laundry detergent*, has joined forces with the film to show how the biggest stains in the universe demand the most powerful clean – in any universe. This press release features mu

      1/8/25 10:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    SEC Filings

    See more
    • Procter & Gamble Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      7/8/25 4:20:53 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      6/9/25 4:19:17 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      6/5/25 6:03:25 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Procter & Gamble downgraded by Redburn Atlantic with a new price target

      Redburn Atlantic downgraded Procter & Gamble from Buy to Neutral and set a new price target of $161.00

      5/1/25 7:44:23 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Procter & Gamble from Sector Perform to Outperform and set a new price target of $177.00

      4/25/25 8:25:38 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble upgraded by DA Davidson with a new price target

      DA Davidson upgraded Procter & Gamble from Neutral to Buy and set a new price target of $209.00 from $160.00 previously

      11/25/24 7:49:48 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcevoy Ashley was granted 185 shares, increasing direct ownership by 5% to 3,636 units (SEC Form 4)

      4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

      6/11/25 2:50:37 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Jimenez Joseph was granted 292 shares, increasing direct ownership by 0.88% to 33,658 units (SEC Form 4)

      4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

      6/11/25 1:27:59 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Woertz Patricia A was granted 185 shares, increasing direct ownership by 0.36% to 50,992 units (SEC Form 4)

      4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

      6/11/25 1:08:56 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • P&G Declares Quarterly Dividend for July 2025

      The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after August 15, 2025 to Common Stock shareowners of record at the close of business on July 18, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on July 18, 2025. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, many of who

      7/8/25 4:15:00 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • The Unstopables™ Unlimited Collection Redefines Laundry Luxury with Fine Fragrances for Everyone

      New scent beads bring high-end fragrances to everyday laundry, making luxury accessible to everyone, everywhere Unstopables announces the launch of the Unlimited Collection, a new line of in-wash laundry scent boosters that make fine fragrance accessible to everyone, everywhere. Inspired by the craftsmanship of prestige perfumes, the Unstopables Unlimited Collection redefines the scent booster category with bold, long-lasting aromas designed to luxe up everyday laundry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708549393/en/ The collection debuts with three elevated fragrances that evoke indulgence and sophistication,

      7/8/25 9:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G to Webcast Discussion of Fourth Quarter 24/25 Earnings Results on July 29

      The Procter & Gamble Company (NYSE:PG) will webcast a discussion of its fourth quarter earnings results on Tuesday, July 29, 2025, beginning at 8:30 a.m. ET. Media and investors may access the live audio webcast at https://www.pginvestor.com. The webcast will also be available for replay. About Procter & Gamble P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approxim

      7/1/25 9:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/22/24 4:50:46 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/9/24 2:20:54 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/2/24 3:44:23 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $PG
    Financials

    Live finance-specific insights

    See more
    • P&G Declares Quarterly Dividend for July 2025

      The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after August 15, 2025 to Common Stock shareowners of record at the close of business on July 18, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on July 18, 2025. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, many of who

      7/8/25 4:15:00 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G Announces Fiscal Year 2025 Third Quarter Results

      Net Sales -2%; Organic Sales +1% Diluted EPS and Core EPS $1.54, each +1% UPDATES FISCAL YEAR SALES and EPS GUIDANCE MAINTAINS CASH RETURN GUIDANCE The Procter & Gamble Company (NYSE:PG) reported third quarter fiscal year 2025 net sales of $19.8 billion, a decrease of two percent versus the prior year. Organic sales, which excludes the impacts of foreign exchange and acquisitions and divestitures, increased one percent versus the prior year. Diluted and core net earnings per share were $1.54, each an increase of 1% versus prior year. Operating cash flow was $3.7 billion, and net earnings were $3.8 billion for the quarter. Adjusted free cash flow productivity was 75%. Adjusted free cash

      4/24/25 7:00:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G Declares Dividend Increase

      The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared an increased quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after May 15, 2025 to Common Stock shareowners of record at the close of business on April 21, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on April 21, 2025. This represents a five percent increase compared to the prior quarterly dividend. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 c

      4/8/25 4:15:00 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary